nach oben

Erschienen in:

01.04.2010 | Original Article

Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Nonalcoholic fatty liver disease (NAFLD) is linked to an increased risk of cardiovascular disease. We aimed to research whether the levels of soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L), markers of endothelial function, are altered in subjects with NAFLD having no confounding factors for atherosclerosis. sCD40L, sP-selectin, and high-sensitivity C-reactive protein (hsCRP) levels, and homeostasis model assessment of insulin resistance (HOMA-IR) indexes were measured in 50 NAFLD subjects and 30 healthy controls. sCD40L, sP-selectin, and hsCRP levels were not significantly different between two groups (P = 0.48, 0.51, and 0.34, respectively). Body mass index, waist circumference, and insulin levels and HOMA indexes were significantly higher in subjects with NAFLD (all P < 0.001). The present data show that sCD40L and sP-selectin may not contribute to the accelerated atherogenesis associated with this clinically relevant condition.

Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: A clinical review. Dig Dis Sci. 2005;50:171–180. doi:10.1007/s10620-005-1267-z.CrossRefPubMed

Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:141–150. doi:10.1042/CS20070402.CrossRef

Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11:105–117. doi:10.1016/j.cld.2007.02.013.CrossRefPubMed

Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia. 2008;51:1947–1953. doi:10.1007/s00125-008-1135-4.CrossRefPubMed

Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Dia Med. 2005;22:1354–1358. doi:10.1111/j.1464-5491.2005.01646.x.CrossRef

Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72–78. doi:10.1016/j.amjmed.2007.08.041.CrossRefPubMed

Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203:581–586.CrossRefPubMed

Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121. doi:10.2337/dc07-0349.CrossRefPubMed

Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240. doi:10.1016/j.atherosclerosis.2006.08.021.CrossRefPubMed

10.

Phipps RP. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA. 2000;97:6930–6932. doi:10.1073/pnas.97.13.6930.CrossRefPubMed

11.

Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395–2400. doi:10.1161/hc4501.099312.CrossRefPubMed

12.

Aukrust P, Müller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614–620.PubMed

13.

Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation. 2003;107:2664–2669. doi:10.1161/01.CIR.0000074043.46437.44.CrossRefPubMed

14.

Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–2268. doi:10.1161/hc4401.099447.CrossRefPubMed

15.

Wagner DD. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993;70:105–110.PubMed

16.

Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: İmplications for atherogenesis? A preliminary report. J Hypertens. 1995;13:1674–1678.PubMed

17.

Davì G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97:953–957.PubMed

18.

Blann AD, Dobrotova M, Kubisz P, McCollum CN. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626–630.PubMed

19.

Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995;92:1693–1696.PubMed

20.

Sakurai S, Inoue A, Koh CS, Owa M, Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med. 1997;2:163–168.PubMed

21.

Shimomura H, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol. 1998;81:397–400. doi:10.1016/S0002-9149(97)00945-4.CrossRefPubMed

22.

Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495.PubMed

23.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed

24.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi:10.1007/BF00280883.CrossRefPubMed

25.

Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63. doi:10.2337/diacare.23.1.57.CrossRefPubMed

26.

Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis. 2001;21:3–16. doi:10.1055/s-2001-12925.CrossRefPubMed

27.

Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18:175–180. doi:10.1097/00042737-200602000-00010.CrossRefPubMed

28.

Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: Role of visceral fat accumulation. Diabetes Care. 2004;27:2498–2500. doi:10.2337/diacare.27.10.2498.CrossRefPubMed

29.

Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–1050. doi:10.1161/01.ATV.0000160613.57985.18.CrossRefPubMed

30.

Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–480. doi:10.1002/hep.20781.CrossRefPubMed

31.

Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutr Metab Cardiovasc Dis. 2007;17:684–698. doi:10.1016/j.numecd.2007.01.007.CrossRefPubMed

32.

Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:41–43.

33.

Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92:4342–4346. doi:10.1073/pnas.92.10.4342.CrossRefPubMed

34.

Kornbluth RS, Kee K, Richman DD. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci USA. 1998;95:5205–5210. doi:10.1073/pnas.95.9.5205.CrossRefPubMed

35.

Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104:1041–1050. doi:10.1172/JCI6993.CrossRefPubMed

36.

Denger S, Jahn L, Wende P, et al. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: Induction of the synthetic phenotype: A possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis. 1999;144:15–23. doi:10.1016/S0021-9150(99)00033-7.CrossRefPubMed

37.

Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399.PubMed

38.

Schönbeck U, Mach F, Sukhova GK, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156:7–14.PubMed

39.

Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Down regulatory effect of statin therapy. J Am Coll Cardiol. 2003;41:275–279. doi:10.1016/S0735-1097(02)02718-3.CrossRefPubMed

40.

Gokulakrishnan K, Deepa R, Mohan V. Soluble P selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism. 2006;55:237–242. doi:10.1016/j.metabol.2005.08.019.CrossRefPubMed

41.

McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16:73–80.PubMed

42.

Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J. 1995;9:866–873.PubMed

43.

Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest. 1986;78:130–137. doi:10.1172/JCI112542.CrossRefPubMed

44.

McEver RP. GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem. 1991;45:156–161. doi:10.1002/jcb.240450206.CrossRefPubMed

45.

Parmentier S, McGregor L, Catimel B, Leung LL, McGregor JL. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM). Blood. 1991;77:1734–1739.PubMed

46.

Blann AD, Lip GYH. Hypothesis: Is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135–138. doi:10.1016/S0021-9150(96)05980-1.CrossRefPubMed

47.

Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction. A new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis. 1997;8:383–390. doi:10.1097/00001721-199710000-00002.CrossRefPubMed

48.

Blann AD, Seigneur M, Boisseau MR, Taberner DA, McCollum CN. Soluble P selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis. 1996;7:789–793. doi:10.1097/00001721-199611000-00008.CrossRefPubMed

49.

Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dsi Sci. 2008;53:1088–1092. doi:10.1007/s10620-007-9981-3.CrossRef

50.

Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455. doi:10.1016/S0002-9343(99)00271-5.CrossRefPubMed

51.

Lizardi-Cervera J, Chavez-Tapia NC, Pérez-Bautista O, Ramos MH, Uribe M. Association among C-reactive protein, fatty liver disease, and cardiovascular risk. Dig Dis Sci. 2007;52:2375–2379. doi:10.1007/s10620-006-9262-6.CrossRefPubMed

52.

Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19:694–698. doi:10.1111/j.1440-1746.2004.03362.x.CrossRefPubMed

53.

Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V, García-Zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82–88.CrossRefPubMed

54.

Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30:387–394. doi:10.1291/hypres.30.387.CrossRefPubMed

55.

Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877–883.PubMed

Titel: Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease
Publikationsdatum: 01.04.2010
Erschienen in: Digestive Diseases and Sciences / Ausgabe 4/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-009-0817-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

CMV in Moderately Active Colitis: Much Ado About Nothing?

Efficacy of Gastric Electrical Stimulation in Improving Functional Vomiting in Patients with Normal Gastric Emptying

Acute Hepatitis Due to Epstein–Barr Virus in an Immunocompetent Patient

Injury to Endoscopic Personnel from Tripping over Exposed Cords, Wires, and Tubing in the Endoscopy Suite: A Preventable Cause of Potentially Severe Workplace Injury

Esophageal Intraepithelial Eosinophils in Dysphagic Patients with Gastroesophageal Reflux Disease